Study showed Hanbeitai is highly similar to the originator, addressing significant unmet clinical needs It is believed that the approval of Hanbeitai will further improve the accessibility of bevacizumab and provide a high-quality option for patients with lung cancer and colorectal cancer." The similarity studies showed no statistically significant difference in efficacy, and the safety are highly similar to the originator. They are also ranked first and second in China, and there is a huge demand for treatment.
Jason Zhu, President of Henlius, said, "Lung cancer and colorectal cancer are ranked second and third with high incidence of cancers in the world, respectively.
#Cyberlink powerdirector 13 reviews trial
While maximizing the value of biosimilar drugs, we will continue advancing the clinical trial process of its combination with in-house immunotherapy products, such as serplulimab, and growing into a more innovative global biopharmaceutical company." The credit goes to all the healthcare professionals, patients and regulatory authorities that have contributed to the studies of Hanbeitai. Wenjie Zhang, Chairman, Executive Director, and CEO of Henlius, said, "We are excited to have Hanbeitai get approved as our fourth product. The pipeline has been further replenished with widened indication coverage including hematological malignancies, solid tumors, auto-immune diseases, etc. Hanbeitai is the company's fourth monoclonal antibody (mAb) approved in China, following rituximab biosimilar Hanlikang, trastuzumab biosimilar Hanquyou (Zercepac Ⓡ in the EU), and adalimumab biosimilar Handayuan. It is indicated for the treatment of metastatic colorectal cancer (mCRC) and unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (nsNSCLC). (2696.HK) announced that bevacizumab biosimilar Hanbeitai, developed and manufactured by Henlius independently, has been approved by the National Medical Products Administration (NMPA). SHANGHAI, China I DecemI Shanghai Henlius Biotech, Inc.